https://mindmedicinelaw.com/briefing/drug-policy-and-human-optimization-a-regulatory-paradox-20260704-19152The Psychedelic Journalen2026-07-05T15:06:27.370956+00:00Drug Policy and Human Optimization: A Regulatory Paradoxdrug policy, psychoactive plants, human optimization, regulatory inconsistencies, liberty and harm, cultural influence, medical gatekeeping, legal status, adult autonomy, substance regulationhttps://mindmedicinelaw.com/briefing/ketamine-s-neural-mechanisms-in-treatment-resistant-depression-20260704-19163The Psychedelic Journalen2026-07-05T15:05:54.039652+00:00Ketamine's Neural Mechanisms in Treatment-Resistant Depressionketamine, treatment-resistant depression, high-order interactions, neural mechanisms, clinical outcomes, brain activity patterns, veterans, EEG, alpha-band, personalized treatmenthttps://mindmedicinelaw.com/briefing/mitochondrial-inflammation-link-in-mdd-psychedelic-potential-20260703-19121The Psychedelic Journalen2026-07-05T22:05:43.496466+00:00Mitochondrial-Inflammation Link in MDD: Psychedelic Potentialmitochondrial dysfunction, inflammation, major depressive disorder, psychedelic compounds, antidepressant strategies, clinical trials, mitochondrial pathways, neuroinflammation, FDA regulations, psychedelic researchhttps://mindmedicinelaw.com/briefing/excitation-inhibition-imbalance-in-sgacc-implications-for-depression-in-dlb-20260703-19166The Psychedelic Journalen2026-07-05T22:05:32.049906+00:00Excitation-Inhibition Imbalance in sgACC: Implications for Depression in DLBsgACC, dementia with Lewy bodies, depression, neurotransmission, glutamatergic, GABAergic, antidepressants, neurochemical changes, psychiatric treatment, synaptic changeshttps://mindmedicinelaw.com/briefing/predictive-processing-in-psychiatry-challenges-and-implications-20260703-19171The Psychedelic Journalen2026-07-05T22:05:23.704413+00:00Predictive Processing in Psychiatry: Challenges and Implicationspredictive processing, psychiatry, mental illness, psychedelic therapies, cultural variability, normative assumptions, PTSD, depression, autism, ADHDhttps://mindmedicinelaw.com/briefing/mystical-experiences-in-ketamine-therapy-insights-and-implications-20260703-19120The Psychedelic Journalen2026-07-05T22:05:13.573416+00:00Mystical Experiences in Ketamine Therapy: Insights and Implicationsketamine-assisted psychotherapy, mystical experiences, psychedelic therapy, anxiety treatment, migraine therapy, subjective experiences, psychological integration, therapeutic outcomes, Hood Mysticism Scale, Outcome Questionnaire-45https://mindmedicinelaw.com/briefing/nondual-meditation-alters-brain-connectome-in-experts-20260703-19155The Psychedelic Journalen2026-07-05T22:05:05.494687+00:00Nondual Meditation Alters Brain Connectome in Expertsnondual meditation, brain connectivity, consciousness research, self-representation, neural integration, mindfulness meditation, fMRI studies, altered states, neuroscience, expert meditatorshttps://mindmedicinelaw.com/briefing/neuroinflammation-s-role-in-depression-implications-for-treatment-20260703-19168The Psychedelic Journalen2026-07-05T15:06:35.942514+00:00Neuroinflammation's Role in Depression: Implications for Treatmentneuroinflammation, depression, immune-brain interface, treatment-resistant depression, biomarker stratification, psychiatry, antidepressants, glial activation, cytokines, precision medicinehttps://mindmedicinelaw.com/briefing/psilocybin-retreats-enhanced-by-targeted-therapy-study-finds-20260703-19118The Psychedelic Journalen2026-07-05T15:06:19.149828+00:00Psilocybin Retreats Enhanced by Targeted Therapy, Study Findspsilocybin retreats, psychotherapy interventions, ACT-PMNR, mental health outcomes, psychedelic therapy, observational study, randomized controlled trials, psychological integration, depression and anxiety, linear mixed model analysishttps://mindmedicinelaw.com/briefing/brain-gut-electrophysiology-in-predicting-antidepressant-response-20260703-19170The Psychedelic Journalen2026-07-05T15:06:11.165312+00:00Brain-Gut Electrophysiology in Predicting Antidepressant Responsebrain-gut electrophysiology, antidepressant response, depression subtypes, personalized treatment, biomarkers, clinical trials, mental health, electrophysiological markers, treatment prediction, clinical decision-makinghttps://mindmedicinelaw.com/briefing/esketamine-s-impact-on-post-op-depression-in-an-surgery-20260703-19165The Psychedelic Journalen2026-07-05T15:06:03.721653+00:00Esketamine's Impact on Post-Op Depression in AN Surgeryesketamine, postoperative depression, acoustic neuroma surgery, clinical trial, perioperative care, mental health outcomeshttps://mindmedicinelaw.com/briefing/brain-lung-axis-in-neurogenic-pulmonary-edema-new-insights-20260703-18847The Psychedelic Journalen2026-07-04T15:06:19.951417+00:00Brain-Lung Axis in Neurogenic Pulmonary Edema: New Insightsneurogenic pulmonary edema, brain-lung axis, central nervous system injury, sympathetic storm, immune dysregulation, therapeutic interventions, adrenergic pathways, inflammatory pathways, clinical management, neuroscience researchhttps://mindmedicinelaw.com/briefing/evaluating-naturally-derived-psilocybin-a-six-criterion-framework-20260703-18796The Psychedelic Journalen2026-07-04T15:06:03.856948+00:00Evaluating Naturally Derived Psilocybin: A Six-Criterion Frameworknaturally derived psilocybin, therapeutic potential, safety and tolerability, pharmacological uniqueness, dose precision, ecological sustainability, controlled trials, regulatory acceptance, standardization, entourage effectshttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-brain-networks-and-gut-brain-axis-20260703-18848The Psychedelic Journalen2026-07-04T15:05:55.721773+00:00Ketamine's Impact on Brain Networks and Gut-Brain Axisketamine, brain networks, gut-brain axis, psychiatric disorders, FMBFN framework, neural dynamics, depression treatment, chronic social defeat stresshttps://mindmedicinelaw.com/briefing/esketamine-and-antidepressants-for-trd-meta-analysis-insights-20260703-18846The Psychedelic Journalen2026-07-04T15:05:47.506929+00:00Esketamine and Antidepressants for TRD: Meta-Analysis Insightsesketamine, treatment-resistant depression, TRD, antidepressants, systematic review, meta-analysis, adverse events, NMDA receptor, supervised care, clinical trialshttps://mindmedicinelaw.com/briefing/fmri-neurofeedback-mood-effects-subjective-success-over-training-20260702-18850The Psychedelic Journalen2026-07-04T15:06:27.816697+00:00fMRI Neurofeedback Mood Effects: Subjective Success Over TrainingfMRI neurofeedback, mood regulation, subjective success, brain activity, psychiatric treatment, clinical trials, neurofeedback efficacy, placebo effect, mental health, neuroscience researchhttps://mindmedicinelaw.com/briefing/variability-in-psilocybe-cubensis-tryptamine-profiles-challenges-standardization-20260702-18833The Psychedelic Journalen2026-07-04T15:06:10.739952+00:00Variability in Psilocybe cubensis Tryptamine Profiles Challenges Standardizationpsilocybe cubensis, tryptamine variability, psilocybin standardization, psychedelic research, clinical applications, biochemical diversity, strain selection, chemical profiling, therapeutic dosing, psychedelic therapieshttps://mindmedicinelaw.com/briefing/psilocybin-mushrooms-cultural-and-therapeutic-roles-reviewed-20260701-18638The Psychedelic Journalen2026-07-04T22:05:41.017439+00:00Psilocybin Mushrooms: Cultural and Therapeutic Roles Reviewedpsilocybin, hallucinogenic mushrooms, mental health treatment, cultural significance, obsessive-compulsive disorder, depression, ethnobotanical uses, recreational use, therapeutic potential, cultural contexthttps://mindmedicinelaw.com/briefing/magnesium-s-role-in-enhancing-morphine-efficacy-in-diabetic-rats-20260701-18688The Psychedelic Journalen2026-07-04T22:05:32.960823+00:00Magnesium's Role in Enhancing Morphine Efficacy in Diabetic Ratsmagnesium ions, morphine efficacy, neuropathic pain, diabetic rats, pain management, NMDAR antagonists, opioid analgesia, clinical trials, neurotrophic factors, public healthhttps://mindmedicinelaw.com/briefing/postoperative-pain-management-in-cancer-new-insights-20260701-18692The Psychedelic Journalen2026-07-04T22:05:22.473515+00:00Postoperative Pain Management in Cancer: New Insightspostoperative pain, cancer patients, behavioral disorders, opioid sparing, multimodal analgesia, personalized medicine, psycho-emotional factors, pain management, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/esketamine-reduces-ciprofol-rate-in-endoscopy-trial-insights-20260701-18855The Psychedelic Journalen2026-07-04T22:05:14.859624+00:00Esketamine Reduces Ciprofol Rate in Endoscopy: Trial Insightsesketamine, ciprofol, gastrointestinal endoscopy, sedation protocols, hemodynamic stability, neuropsychiatric symptoms, clinical trials, hypotension, procedural sedation, adverse eventshttps://mindmedicinelaw.com/briefing/intranasal-esketamine-and-itbs-for-severe-depression-a-case-study-20260701-18858The Psychedelic Journalen2026-07-04T22:05:07.360323+00:00Intranasal Esketamine and iTBS for Severe Depression: A Case Studyintranasal esketamine, theta-burst stimulation, treatment-resistant depression, suicidal ideation, psychiatric emergency, neuroscience, clinical trials, mental health treatment, depression therapy, innovative treatmentshttps://mindmedicinelaw.com/briefing/comparative-efficacy-of-tf-cbt-and-emdr-in-ptsd-treatment-20260630-19138The Psychedelic Journalen2026-07-05T22:05:53.116370+00:00Comparative Efficacy of TF-CBT and EMDR in PTSD TreatmentPTSD treatment, TF-CBT, EMDR, trauma-focused therapy, clinical guidelines, psychotherapy efficacy, mental health, post-traumatic stress disorderhttps://mindmedicinelaw.com/briefing/incentive-misalignment-in-psychedelic-medicine-economic-challenges-20260630-18806The Psychedelic Journalen2026-07-04T22:05:50.483788+00:00Incentive Misalignment in Psychedelic Medicine: Economic Challengesincentive misalignment, psychedelic medicine, healthcare economics, patient autonomy, healthspan-oriented care, reimbursement models, pharmaceutical influence, evidence-based care